Project Grant R01HL188348
Award Date 8/20/26
Completion Date 5/31/30
Dollars Obligated $633K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded Trustees of Boston University $100,228 on December 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate enhancement of engraftment potential in human hematopoietic stem cells. The research addresses the challenge of preserving hematopoietic stem cell functionality during the ex vivo culture steps required for gene editing therapies. The project employs multi-modal profiling of...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $2,712,905 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop safe, effective, and scalable curative therapies for hemoglobinopathies including sickle cell disease, alpha-thalassemia, beta-thalassemia, and Fanconi anemia by targeting hematopoietic stem cells in vivo using antibody-directed, lipid nanoparticle delivery systems. The research strategy...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,932 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer and scale production of red blood cells derived from human induced pluripotent stem cells (iPSCs) for two high-impact applications: alloantibody detection and neonatal transfusion therapy. The project addresses urgent clinical needs in two vulnerable patient populations. Sickle cell disease...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of California, San Diego $168,795 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on proteostasis in hematopoietic stem cell development. The project, titled "Proteostasis in Hematopoietic Stem Cell Development," addresses dysfunction in inherited bone marrow failure syndromes by investigating protein homeostasis disruption in...
- This five-year Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $153,117 in obligated funding beginning August 1, 2025, through July 31, 2030. The award supports a physician-scientist's career development and independent research program focused on improving hematopoietic stem and progenitor cell (HSPC) transplantation outcomes through investigation of cellular crosstalk mechanisms between...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1.137883 million on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the dynamics and plasticity of the hematopoietic stem cell niche. The funded work defines niche dynamics and plasticity across development, regeneration, and hematological disease; uncovers the mechanisms regulating these processes; and develops approaches to enhance...
- Federal Grant Award Summary The University of Pennsylvania received a $240,552 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 10, 2025, with completion targeted for January 31, 2026. The project, "Unraveling the Cell Networks in Bone Marrow Through Transcriptomic and Epigenetic Profiling," will generate a comprehensive single-cell transcriptomic and regulomic map of human bone...
- The National Heart, Lung, and Blood Institute awarded the University of Florida $597,817 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop resources for enhancing hematopoietic stem cell transplantation outcomes. The research aims to humanize the bone marrow vascular niche to study hematopoietic stem cell and vascular interactions and function. The project will establish technologies to isolate and cultivate human primary endothelial cells from bone...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded The Johns Hopkins University $379,509 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop mesenchymal stem cell (MSC) therapies with enhanced immunosuppressive efficacy for graft-versus-host disease treatment through mechanical programming of cell microenvironments. The research focuses on identifying and providing optimal mechanical cues during MSC...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $580,043 for Project Grant R01HL185283 on July 16, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds investigation of arterial vascular niche regulation in generating engraftable hematopoietic stem cells (HSCs) from induced pluripotent stem cells (iPSCs). The research addresses the limited engraftment capability and skewed lineage potential of hematopoietic cells derived...